Identification of hepatic tamoxifen-DNA adducts in mice: α-(N2-deoxyguanosinyl)tamoxifen and α-(N2-deoxyguanosinyl)tamoxifen N-oxide

Carcinogenesis

Volumn 21, Issue 9, 2000, Pages 1737-1744

  Umemoto, Atsushi ^a   Monden, Yasumasa ^a   Suwa, Masato ^b   Kanno, Yoshikazu ^b   Suzuki, Masanobu ^b   Lin, Chun Xing ^a   Ueyama, Yuji ^a   Momen, Md Abdul ^a   Ravindernath, Anisetti ^c   Shibutani, Shinya ^c   Komaki, Kansei ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ALKALINE PHOSPHATASE; ALPHA (N2 DEOXYGUANOSINYL)TAMOXIFEN; ALPHA (N2 DEOXYGUANOSINYL)TAMOXIFEN N OXIDE; ALPHA ACETOXYTAMOXIFEN N OXIDE; DEOXYGUANOSINE PHOSPHATE; ION; NORTAMOXIFEN; NUCLEOTIDE; PHOSPHORUS 32; RADIOACTIVE MATERIAL; TAMOXIFEN CITRATE; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DNA ADDUCT; DOSE LIVER FUNCTION RELATION; DRUG IDENTIFICATION; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; LIVER; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STEREOISOMERISM;

EID: 0033858986     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.9.1737     Document Type: Article

References (41)

1. The development of tamoxifen for breast cancer therapy
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
4. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
5. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignacies. Stockholm Breast Cancer Study Group
6. Quantifying the carcinogenicity of antineoplastic drugs
7. Heritable and cancer risks of exposures to anticancer drugs: Inter-species comparisons of covalent deoxyribonucleic acid-binding agents
8. Two-year carcinogenicity study of tamoxifen in Alderley Park Wister-derived rats
9. Major difference in the hepatocarcinogenecity and DNA adduct froming ability between toremifene and tamoxifen in female Crl:CD(BR) rats
10. Antiestrogen therapy: Uncertainties and risk assessment
11. 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method
12. Identification of the major tamoxifendeoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
13. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen
14. Minor products of reaction of DNA with α-acetoxytamoxifen
15. α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts
16. Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts
17. The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation
18. Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy
19. Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
20. N-demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
21. Tamoxifen-DNA adducts formed by α-acetoxytamoxifen N-oxide
22. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes
23. Presence of mucosa-specific DNA adduct in human colon: Possible implication for colorectal cancer
24. 32P-postlabeling test for structurally diverse DNA adducts
25. 2-deoxyguanosinyl)tamoxifen
26. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen
27. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen
28. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism
29. 5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen
30. 5-ethyl]tamoxifen
31. 2 cell line, human liver homogenate and patients on long-term therapy for breast cancer
32. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment
33. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite
34. Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen
35. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
36. Cytochrome P-450-mediated activation and irreversible binding of the antioestrogen tamoxifen to proteins in rats and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation
37. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation
38. Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethylaminoethoxy)-phenyl]-1, 2-diphenyl-1-buten-3-ol N-oxide
39. Interspecies differences in cancer susceptibility and toxicity
40. Lifetime and reactivity of an ultimate tamoxifen carcinogen: The tamoxifen carbocation